Cargando…
Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries
Even for products centrally approved, each European country is responsible for national market access after European Medicines Agency (EMA) approval. This step can result in inequalities in terms of access, due to different opinions about the therapeutic value assessed by Health Technology Assessmen...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854989/ https://www.ncbi.nlm.nih.gov/pubmed/35185551 http://dx.doi.org/10.3389/fphar.2021.823199 |